Nigeria Signed a U.S. Health Pact; Ghana Rejected Its Proposal. What Do the Records Show?

Nigeria and Ghana took different decisions on proposed health cooperation under the United States' America First Global Health Strategy. Nigeria signed a five-year health memorandum with the U.S. on 19 December 2025. Ghana rejected its proposed compact after its cabinet raised concerns about health records, pathogen information, domestic funding, and the inspection of medical products, according to President John Mahama's account. The two countries negotiated separate documents, so Ghana's objections cannot simply be treated as the terms Nigeria accepted.

Nigeria's signed memorandum covers disease surveillance, laboratories, treatment, and health-system financing. Nigeria's Health Ministry says it anticipates nearly US$2 billion in U.S. grants alongside nearly US$3 billion in Nigerian health spending through 2030. The often-cited roughly US$5 billion figure combines both countries' planned contributions; it is not a US$5 billion U.S. grant.

The documents also raise questions that deserve precise answers. Nigeria's memorandum envisages a further data-sharing arrangement, regulated U.S. access for specified audits, and a committee to consider pathogen-specimen sharing case by case. A separate signed specimen-sharing agreement entered into force on 18 January 2026. It permits sharing relevant specimens and data with the U.S. government and, for specified research purposes, capable U.S. entities. The complete detailed data-sharing arrangement was not included in the public copy GSR examined.

Ghana's president said its proposal would have prevented Ghana's regulator from inspecting medical products supplied under the programme. Nigeria's published memorandum instead refers to a NAFDAC–U.S. FDA framework and regulatory reliance to accelerate evaluation. GSR has not found a blanket removal of NAFDAC's inspection authority in that text. That distinction warrants confirmation from NAFDAC itself.

The contrast in process is as significant as the contrast in outcome. Ghana's rejection followed a cabinet-level review in which President Mahama publicly stated the grounds for refusal. Nigeria's signing followed an executive decision with no publicly recorded legislative review. That does not make Nigeria's agreement harmful — it may contain none of the provisions that alarmed Ghana's cabinet. But it means the Nigerian public has no equivalent public record against which to test that claim. The National Assembly has not, as of the date of this report, published any committee review of the agreement.

There is a broader pattern here. The U.S. has pursued bilateral health cooperation agreements across sub-Saharan Africa with increasing frequency since 2024, often framed around pandemic preparedness and the post-COVID restructuring of global health architecture. Several of these agreements have been signed at the executive level without parliamentary ratification. The legal question — whether such frameworks constitute treaties requiring legislative approval under each country's constitution — has been raised by civil society groups in Nigeria, Ghana, and Kenya, and has not been definitively resolved in any of those jurisdictions.

GSR is seeking further records and explanations from the relevant Nigerian and U.S. authorities, particularly the detailed data-sharing terms, implementation plan, specimen-governance decisions, and regulatory safeguards. This is an ongoing inquiry. We will update this article as additional documents and verifiable responses become available, and will correct any finding that new evidence changes.